Naltrexon Accord (Naltrexone Hydrochloride)

Naltrexone, the active ingredient in Naltrexon Accord, is an opioid antagonist presented as an oral tablet for oral use. It is used to support the management of alcohol dependence and opioid dependence in adults.\n\nGNH India supplies Naltrexon Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Naltrexon Accord, an opioid antagonist, is indicated for conditions related to alcohol and opioid use disorders.\n\nAlcohol dependence: helps maintain abstinence and reduces cravings.\nOpioid dependence: blocks opioid effects to support detoxification and relapse prevention.\nAlcohol use disorder: lowers the risk of relapse after treatment.

Naltrexon Accord may cause a range of adverse reactions.\n\nCommon Side Effects:\n- Nausea\n- Headache\n- Dizziness\n- Fatigue\n- Insomnia\n- Abdominal discomfort\n\nSerious or Rare Side Effects:\n- Hepatotoxicity or elevated liver enzymes\n- Severe allergic reactions, including anaphylaxis\n- Depression or suicidal thoughts\n- Acute hepatitis\n- Stevens‑Johnson syndrome or other severe skin reactions\n- Cardiovascular events such as hypertension

When prescribing Naltrexon Accord, clinicians should consider several safety measures.\n\nAssess liver function: obtain baseline hepatic tests because the drug is metabolized in the liver.\nAvoid use in acute opioid withdrawal: may precipitate severe withdrawal symptoms.\nMonitor for depression: watch for mood changes or suicidal ideation.\nUse caution in renal impairment: dosage adjustment may be required.\nStore at ambient temperature: keep below 25°C, protect from moisture and store in the original packaging.

Naltrexon Accord can interact with several medication classes.\n\nMajor Interactions (Avoid):\n- Opioid analgesics: may precipitate acute withdrawal.\n- Alcohol: can increase sedation and hepatic strain.\n- Strong CYP3A4 inhibitors: may raise naltrexone plasma levels.\n- Disulfiram: additive risk of hepatotoxicity.\n\nModerate Interactions (Monitor Closely):\n- CYP2D6 substrates: possible altered metabolism.\n- Benzodiazepines: enhanced central nervous system depression.\n- Antidepressants: monitor for mood alterations.